Intravenous Magnesium Sulfate for Acute Severe Asthma
For adults and adolescents with acute severe asthma who remain unresponsive after 1 hour of intensive treatment with inhaled short-acting β2-agonists, systemic corticosteroids, and oxygen, administer a single intravenous bolus of 2 g magnesium sulfate diluted in 50–100 mL of normal saline or 5% dextrose, infused over 20 minutes. 1, 2, 3
Indications for IV Magnesium Sulfate
Reserve IV magnesium sulfate for life-threatening exacerbations or severe exacerbations that remain refractory after 60–90 minutes of standard therapy (oxygen, nebulized albuterol every 20 minutes × 3 doses, and systemic corticosteroids). 1
The National Asthma Education and Prevention Program considers IV magnesium a conditional recommendation for patients with life-threatening features (inability to speak, altered mental status, intercostal retractions, worsening fatigue, PaCO₂ ≥42 mmHg) or those whose FEV₁ or PEF remains <40% predicted despite 1 hour of intensive conventional treatment. 1
Do not use IV magnesium in mild-to-moderate exacerbations; it has no apparent value in patients with less severe disease. 1
Dosing and Administration
Standard Adult Dose
Administer 2 g (or 1.2–2 g) IV magnesium sulfate over 15–20 minutes as a single bolus. 2, 3, 4
Dilute the dose in 50–250 mL of 5% dextrose or 0.9% sodium chloride to achieve a concentration ≤20% before infusion. 2
The maximum infusion rate should not exceed 150 mg/minute (1.5 mL of a 10% solution per minute) except in severe eclampsia with seizures; this FDA guideline applies broadly to magnesium administration. 2
Pediatric Dose
For children with moderate-to-severe acute asthma, administer 40 mg/kg IV magnesium sulfate (maximum 2 g) over 20–30 minutes. 5, 6
This higher weight-based dose (40 mg/kg) has shown remarkable improvement in short-term pulmonary function and significantly greater discharge rates compared to placebo in children aged 6–18 years. 5
Repeat Dosing
Current guidelines recommend a single bolus dose only; repeat dosing is not part of standard emergency department protocols. 1, 3
Continuous magnesium infusions (administered over >4–24 hours at 18.4–50 mg/kg/h) have been used in refractory status asthmaticus requiring PICU admission, but this practice is reserved for children with life-threatening disease unresponsive to all other therapies and requires intensive monitoring for hypotension, muscle weakness, and supratherapeutic magnesium levels. 7
For emergency department management, do not administer repeat boluses; if the patient fails to improve after a single dose, escalate to ICU-level care and consider intubation. 1
Contraindications
Severe renal insufficiency is a relative contraindication; in patients with renal failure, the maximum dose is 20 g over 48 hours with frequent serum magnesium monitoring. 2
Atrioventricular block is a contraindication to IV magnesium. 8
Myocardial damage contraindicates magnesium use. 2
Avoid in patients with known hypersensitivity to magnesium sulfate. 2
Monitoring Requirements
During Infusion
Monitor vital signs (heart rate, blood pressure, respiratory rate) and oxygen saturation continuously during and for at least 30 minutes after the infusion. 8, 6
Assess for hypotension, the most common clinically significant adverse event, occurring in up to 16.6% of patients receiving prolonged infusions. 7
Monitor for flushing, fatigue, nausea, headache, and sedation—the most frequently reported side effects. 3, 7
Laboratory Monitoring
Serum magnesium levels are not routinely required for a single bolus dose in patients with normal renal function. 3
If continuous infusions are used (PICU setting only), target serum magnesium concentrations of 4–6 mg/dL and monitor levels every 6–12 hours. 7
Clinical Response Assessment
Reassess FEV₁ or PEF, clinical asthma score, and vital signs 20–30 minutes after completing the magnesium infusion. 5, 6
Patients receiving IV magnesium show peak improvement in pulmonary function at 20–30 minutes, with sustained benefit through 90–110 minutes. 5, 6
Expected Efficacy
IV magnesium sulfate reduces hospital admissions by approximately 7 per 100 adults treated (OR 0.75,95% CI 0.60–0.92), based on high-quality evidence from 972 patients. 3
Patients treated with 40 mg/kg IV magnesium in pediatric studies were significantly more likely to be discharged home (50% vs. 0% in placebo groups). 5
Improvement in spirometry is modest but consistent: mean improvement in PEF of 2.4 L/min greater than placebo in adults, and 25.8% absolute improvement from baseline at 110 minutes in children. 3, 5
Common Pitfalls and Caveats
Do not delay intubation if respiratory failure is imminent; magnesium is an adjunct therapy, not a substitute for mechanical ventilation in patients with altered mental status, inability to speak, or PaCO₂ ≥42 mmHg. 1
Ensure the patient has already received at least three doses of nebulized albuterol (every 20 minutes) and systemic corticosteroids before administering magnesium; it is not a first-line therapy. 1
Infuse magnesium slowly (over 20 minutes, not as a rapid push) to minimize hypotension and flushing. 2, 5
Use a separate IV line if the patient is receiving calcium-containing solutions or sodium bicarbonate, as these can precipitate with magnesium sulfate. 2
Nebulized magnesium sulfate is not recommended; the most recent high-quality evidence (3Mg trial, n=1109) found no benefit over placebo for nebulized magnesium (OR 0.96 for hospital admission, no improvement in breathlessness or PEFR). 9, 4
Concurrent Therapies
Continue nebulized albuterol and ipratropium bromide during and after magnesium administration; magnesium is an adjunct, not a replacement. 1, 10
Administer supplemental oxygen to maintain SpO₂ ≥90% throughout treatment. 1
Ensure systemic corticosteroids (oral prednisone 40–60 mg or IV methylprednisolone 60–125 mg) have been given before or concurrently with magnesium. 1